Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Target Price at $56.57

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been assigned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $56.57.

Several research analysts recently weighed in on the stock. StockNews.com downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. HC Wainwright assumed coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They issued a “buy” rating and a $58.00 target price on the stock.

Agios Pharmaceuticals Stock Up 1.9 %

Shares of Agios Pharmaceuticals stock opened at $27.66 on Tuesday. The firm has a market cap of $1.58 billion, a PE ratio of 2.44 and a beta of 0.83. Agios Pharmaceuticals has a twelve month low of $23.42 and a twelve month high of $62.58. The business has a 50-day moving average price of $30.87 and a 200 day moving average price of $38.78.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, sell-side analysts expect that Agios Pharmaceuticals will post -6.85 EPS for the current year.

Insider Buying and Selling

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm’s stock in a transaction dated Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the sale, the director now directly owns 149,220 shares in the company, valued at approximately $3,864,798. This trade represents a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.93% of the stock is currently owned by company insiders.

Institutional Trading of Agios Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Agios Pharmaceuticals by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company’s stock worth $185,045,000 after acquiring an additional 85,339 shares during the period. State Street Corp grew its holdings in shares of Agios Pharmaceuticals by 10.2% during the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after purchasing an additional 216,484 shares during the period. Jefferies Financial Group Inc. acquired a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth about $49,290,000. Geode Capital Management LLC raised its holdings in Agios Pharmaceuticals by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after buying an additional 6,101 shares during the period. Finally, Frazier Life Sciences Management L.P. lifted its position in Agios Pharmaceuticals by 2.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company’s stock valued at $35,152,000 after buying an additional 25,600 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.